Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

作者：N. Bartlett, L. Sehn, M. Matasar, S. Schuster, S. Assouline, P. Giri, J. Kuruvilla, M. Canales, S. Dietrich, K. Fay, M. Ku, L. Nastoupil, M. Wei, S. Yin, I. To, Huang Huang, Juliana Min, E. Penuel, L. Budde · 发表于：Blood · 年份：2022 · DOI：10.1182/blood-2022-157691 · 被引用次数：29